Sugi Predict

Sugi Predict / Compounds / SCHEMBL1810795

SCHEMBL1810795

SCHEMBL1810795

N#Cc1ccc(-c2cc[nH]n2)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 8/20 0.48
▸ CASP1 P29466 1/20 0.47
▸ TRPV4 Q9HBA0 1/20 0.43
▸ CYP11B1 P15538 5/20 0.43
▸ EGLN2 Q96KS0 1/20 0.41
▸ HPGD P15428 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ KMO O15229 2/20 0.39
▸ EIF4E P06730 1/20 0.39
▸ AR P10275 4/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16330842 0.98 CYP11B2 (0.47) CYP11B2CASP1TRPV4CYP11B1EGLN2
Hydrochloric Acid SCHEMBL13732341 0.86 NOTUM (0.49) CYP11B2CASP1CYP11B1AR
SCHEMBL1816526 0.81 S1PR1 (0.41) CYP11B2CYP11B1EGLN2HPGDAR
SCHEMBL21996431 0.81 CYP11B2 (0.52) CYP11B2CYP11B1
SCHEMBL3909066 0.81 AR (0.36) CYP11B2CASP1CYP11B1AR
SCHEMBL1829344 0.79 AHR (0.50) HPGDLMNAKMOALDH1A1
SCHEMBL6696076 0.77 PGR (0.42) CYP11B2CYP11B1
SCHEMBL15657561 0.77 CTSK (0.38) CYP11B2CYP11B1ALDH1A1
SCHEMBL21996361 0.77 AR (0.54) EGLN2AR
SCHEMBL6787087 0.75 ALDH1A1 (0.46) HPGDKMOKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583840-B2 Method for the preparation of androgen receptor antagonists and intermediates thereof ORION CORPORATION (FI) 2026-03-24 — — US claimed
WO-2025037054-A1 PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF ORION CORPORATION (FI) 2025-02-20 — — WO claimed
CN-118772058-A Synthesis method and application of 2-chloro-4- (1H-pyrazol-3-yl) benzonitrile 济南尚博医药股份有限公司 2024-10-15 — — CN claimed
US-20230174517-A1 METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF ORION CORPORATION (FI) 2023-06-08 — — US claimed
EP-4149938-A1 METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF Orion Corporation (FI) 2023-03-22 — — EP claimed
CN-115605470-A Process for preparing androgen receptor antagonists and intermediates thereof 奥赖恩公司（FI） 2023-01-13 — — CN claimed
WO-2021229145-A1 METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF ORION CORPORATION (FI) 2021-11-18 — — WO claimed
CN-113527208-A Method for preparing 2-chloro-4- (1H-pyrazol-3-yl) benzonitrile by one-step method 江西金丰药业有限公司 2021-10-22 — — CN claimed
CN-107428695-B Process for preparing androgen receptor antagonists and intermediates thereof 奥赖恩公司 2021-03-16 — — CN claimed
EP-3280710-B1 PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF ORION CORP (FI) 2020-02-26 — — EP claimed
US-10189789-B2 Process for the preparation of androgen receptor antagonists and intermediates thereof ORION CORPORATION (FI) 2019-01-29 — — US claimed
US-20180099938-A1 PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF ORION CORPORATION (FI) 2018-04-12 — — US claimed
EP-3280710-A1 PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF Orion Corporation (FI) 2018-02-14 — — EP claimed
WO-2016162604-A1 PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF ORION CORPORATION (FI) 2016-10-13 — — WO claimed
CN-122103101-A Preparation method of medicine intermediate 2-chloro-4- (1H-pyrazol-3-yl) benzonitrile — 2026-05-29 — — CN disclosed
CN-122103101-A Preparation method of medicine intermediate 2-chloro-4- (1H-pyrazol-3-yl) benzonitrile — 2026-05-29 — — CN disclosed
US-12583840-B2 Method for the preparation of androgen receptor antagonists and intermediates thereof ORION CORPORATION (FI) 2026-03-24 — — US disclosed
CN-102596910-A Androgen receptor modulating compounds ORION CORP 2012-07-18 — — CN disclosed
WO-2011051540-A9 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-06-21 — — WO disclosed
WO-2011051540-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174517-A1 METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF AR, GNRHR, FSHR CYP11B2 22/4885CASP1 4598/4885TRPV4 776/4885
US-20180099938-A1 PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF AR, NR5A1, GNRHR CYP11B2 95/4885CASP1 1720/4885TRPV4 475/4885
US-12583840-B2 Method for the preparation of androgen receptor antagonists and intermediates thereof AR, FSHR, PKD1 CYP11B2 221/4885CASP1 3295/4885TRPV4 120/4885
US-10189789-B2 Process for the preparation of androgen receptor antagonists and intermediates thereof AR, NR5A1, GNRHR CYP11B2 95/4885CASP1 1720/4885TRPV4 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.